PubMed-compiled information sheet
This sheet was compiled from PubMed (NIH) abstracts using AI assistance. Every factual claim is cited to a real PubMed article (see the source list). It has not yet been human-reviewed — confirm with a healthcare provider before use.
Compiled from 30 PubMed articles · model: gemma4:31b
Summary
Background
Traditional uses
Active compounds
Mechanism of action
Clinical evidence
Bayberry pollen extract caused positive nasal challenges in 92% of allergic rhinitis subjects and positive bronchial challenges in 57% of subjects with extrinsic asthma [PMID:1527315].
Ethanolic extracts of M. cerifera showed antiproliferative potential against HepG2 and HeLa human cancer cell lines [PMID:34982821]. Triterpenoids (betulin, ursolic acid) and myricanol exhibited cytotoxic activities against HL60 (leukemia), A549 (lung), and SK-BR-3 (breast) cancer cell lines [PMID:27492128].
M. cerifera extract potently reduced endogenous and overexpressed tau protein levels in cells and murine brain slices, with myricanol being the most effective component [PMID:21141876].
Safety & adverse effects
Evidence summary
PubMed sources
- 1.PMID: 36159598 (2022) — Myrica cerifera, a Medicinal Plant of the Lumbee Tribe, has Antibacterial and Nematicidal Properties. · American journal of undergraduate research
- 2.PMID: 1527315 (1992) — Nasal and bronchial provocation challenges with bayberry (Myrica cerifera) pollen extract. · The Journal of allergy and clinical immunology
- 3.PMID: 30474534 (2020) — Effects of Myricitrin and Relevant Molecular Mechanisms. · Current stem cell research & therapy
- 4.PMID: 11045444 (2000) — Oleanane acid from Myrica cerifera. · Chemical & pharmaceutical bulletin
- 5.PMID: 21141876 (2011) — The diarylheptanoid (+)-aR,11S-myricanol and two flavones from bayberry (Myrica cerifera) destabilize the microtubule-associated protein tau.